MINUTES FOR THE BIOSAFETY COMMITTEE

Thursday January 29, 2026

PRESENT: Arrigo "Ricky" De Benedetti, Ph.D., Chairman.

Christopher Schmoutz, Ph.D., Vice-Chairman

Stephanie Ander, Ph.D.	Ana Maria Dragoi, Ph.D.
Jessica Esparza, Ph.D.	Omar Franco, M.D., Ph.D
Hongyan Guo, Ph.D.	Seong Kim, Ph.D
DeMonzo Mcginnis, B.S. (BSO)	Rebecca Murphy, Ph.D.
Hugh Price, DVM	Krista Queen, Ph.D.
Xinggui Shen, Ph.D.	Hong Sun, Ph.D.
Tousif Sultan, Ph.D	Vesna Tesic, Ph.D.

ABSENT:

Sarah Harold, B.S.	Ashley Krukowsky, (OSP)
Michael Stroud, B.S., Safety	Hong Sun, Ph.D.

I. **MEETING CALLED TO ORDER:** The meeting called January 29, 2026 at 3pm with a quorum of 15 voting members.

II. **Approval of Minutes from the previous meeting.** Minutes December 11, 2025

III. **NEW PROTOCOLS TO BE CONSIDERED:**

B25-007/Microbiology – MOLECULAR PATHOGENESIS, IMMUNITY, AND ECOLOGY OF ARTHROPOD-BORNE BSL3 VIRUSES. This protocol was previously in the CONTINGENT APPROVAL section as voted by the BSL3 subcommittee. The PI has submitted her response to the BSL3 subcommittee review which is no longer functioning. This is the first time the main IBC will be reviewing the protocol. The committee determined by unanimous vote for the protocol to remain in the CONTINGENT APPROVAL category with the following comments:

- Clarify the justification/explanation between the use of chimeric viruses and native viruses (i.e. why is it necessary to validate results from chimeric viruses with the native virus).
- Add statement that all work described in the procedural risks section is being done in the BSL3 with equipment available in the BSL3.

IV. **TABLED PROTOCOLS WITH MODIFICATIONS REQUIRED:** The following were approved in December and was reported to the IBC. The sponsors of both clinical trials are requesting Biosafety Protocols.

B26-009 – Hematology/Oncology – Clinical Trial:
A Phase 3 Study of a arlocabtagene autoleucel, a GPRC5D-directed CAR T Cell Therapy (Quintessential 2 CA 088 clinical trial) in Participants with Relapsed or Refractory Multiple Myeloma and Refractory to Lenalidomide.

B26-010 – Hematology/Oncology – Clinical Trial:
A phase 2, open-label, multicenter study of MB-105 in patients with CD5 positive (CD5+) relapsed / refractory T-cell lymphoma (r/r TCL).

V. CONTINGENT APPROVALS: *None*

VI. TERMINATIONS: *None*

VII. Old Business: *None*

VIII. NEW BUSINESS: Modifications **FULLY APPROVED** by unanimous vote:

B25-005 Microbiology – BSL2 The PI is requesting addition of Sindbis/MADV. Chimeric Sindbis/MADV is highly attenuated in animal models and proposed as a vaccine candidate.

B26-006/Microbiology -Room Addition

IX. ANNUAL RENEWALS: No renewals for the month of January.

X. NON-RESPONDER ANNUAL RENEWALS:

B08-004/Pediatrics has not submitted his 2025 annual renewal.

XI. ADD/DELETE MEMOS: All listed completed training and were approved by unanimous vote unless indicated.
B21-001/Pathology – ADD: Postdoc; training complete.
B23-003/Neurosurgery – ADD: RA; training complete
B26-008/Physiology – ADD: Postdoc, and R.A.; training complete.

XII. Contingent ADD MEMOS: Contingent until training is complete.
B21-002/Pathology
ADD: Resident **(training incomplete)**

Adjourn: 4pm

Respectfully submitted:

_____
Sarah Harold, B.S.
Assistant Director, Assurance Committees

Approved:

_____
Arrigo DeBenedetti, Ph.D.
Chair, Biosafety Committee